{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:04:23Z","timestamp":1767852263146,"version":"3.49.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"8","funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","award":["HI19C1328"],"award-info":[{"award-number":["HI19C1328"]}],"id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2024,8,2]]},"DOI":"10.1080\/14740338.2023.2294924","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T10:32:48Z","timestamp":1702463568000},"page":"1007-1015","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer"],"prefix":"10.1080","volume":"23","author":[{"given":"Joo-Young","family":"Byun","sequence":"first","affiliation":[{"name":"Health Outcomes division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA"},{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sola","family":"Han","sequence":"additional","affiliation":[{"name":"Health Outcomes division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiham","family":"Qdaisat","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanhyun","family":"Park","sequence":"additional","affiliation":[{"name":"Health Outcomes division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909530"},{"key":"e_1_3_7_5_1","unstructured":"Drugs@FDA: FDA-Approved Drugs [cited 2023 Oct 15]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1031"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01171"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.10.021"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.111.962019"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1549222"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.82"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b12-00778"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euz058"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.613625"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.08.067"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.433"},{"issue":"6","key":"e_1_3_7_20_1","first-page":"523","article-title":"Drug induced QT prolongation","volume":"14","author":"Zareba W","year":"2007","unstructured":"Zareba W. Drug induced QT prolongation. Cardiol J. 2007;14(6):523\u2013533.","journal-title":"Cardiol J"},{"key":"e_1_3_7_21_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. E14 Clinical Evaluation Of QT\/QTc Interval Prolongation And Proarrhythmic Potential For Non-Antiarrhythmic Drugs. FDA Guidance Documents. 2012 [cited 2023 Dec 15]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0."},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00234-x"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eupc.2005.05.010"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211073823"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01217-4"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.26502\/fccm.92920263"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.655808"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.011"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2013.12.002"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04415.x"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.10.006"},{"key":"e_1_3_7_32_1","unstructured":"Medicare.gov [2023 Jan 31]. Available from: https:\/\/www.medicare.gov\/basics\/get-started-with-medicare"},{"key":"e_1_3_7_33_1","unstructured":"SEER-Medicare: brief Description of the SEER-Medicare database [2023 Jan 31]. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/"},{"key":"e_1_3_7_34_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program [2023 Jan 31]. Available from: https:\/\/seer.cancer.gov\/registries\/cancer_registry\/index.html"},{"key":"e_1_3_7_35_1","unstructured":"NCI. SEER program. ICD-O-3 Coding Materials [cited 2023 Oct 15]. Available from: https:\/\/seer.cancer.gov\/icd-o-3\/"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.15441\/ceem.17.261"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25005"},{"key":"e_1_3_7_38_1","unstructured":"National Cancer Institute. Division of Cancer Control & Population Sciences. Comorbidity SAS Macro (2021 version) [cited 2023 Apr 7]. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/macro-2021.html"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab158"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007724"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2005.01589.x"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1164028"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0316-6"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211020798"},{"issue":"1","key":"e_1_3_7_46_1","first-page":"vdab188","article-title":"Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study","volume":"4","author":"Peled N","year":"2022","unstructured":"Peled N, Kian W, Inbar E, et al. Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Neurooncol Adv. 2022 Jan;4(1):vdab188.","journal-title":"Neurooncol Adv"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02561-z"},{"key":"e_1_3_7_48_1","unstructured":"National Cancer Institute. SEER-Medicare. Measures that are limited or not available in the data [cited 2023 Apr 26]. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/measures.html#2"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.10.1178"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2294924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T18:29:56Z","timestamp":1727202596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2294924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,2]]}},"alternative-id":["10.1080\/14740338.2023.2294924"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2294924","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}